Use Case:

Multi-Centre, Central Contouring Personalized Dosimetry

Lu-DOTATATE Treatment in Patients with 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
(ClinicalTrials.gov Identifier: NCT02743741)

In this multi-centre trial, each patient (n=195 from 4 centres) can receive up to 4 cycles of Lutetium-Dotatate (¹⁷⁷Lu-Dota) therapy for neuroendocrine tumors (NETs). Prior to enrollment, patients receive a Gallium-68 SPECT-CT scan that must be reviewed by a tumor board to determine eligibility^†.

The PI requested the ability to anonymize, send, and review images. In addition, to be able to contour tumors and create a cycle-to-cycle dosimetry report as therapy continues.

For enrolled patients, SPECT-CT images are collected by QIPCM at every cycle of ¹⁷⁷Lu-Dota therapy using the QIPCM-issued image de-identification and transfer pipeline. Specified delegates were granted permission to view and contour this trial’s images on the QIPCM platform. QIPCM developed an extended workflow in MIM software so that physicians can themselves draw and process contours to generate dosimetry reports in PDF format. Each report can then be reviewed by a physicist and a physician.

^{† 68}Ga (for diagnosis) and ¹⁷⁷Lu-Dota (for therapy) both target cell surface somatostatin receptors (SSTCs) which are commonly expressed in NETs.

Requirement	QIPCM Solution
Scanner QA at Various Sites	Scanner consultation & QA by QIPCM
Image Anonymization and Transfer from Multiple Institutions	Custom pipeline for de-identification and secure transfer from each institution to the QIPCM repository
Image QA	Image QA by QIPCM
Centralized Storage with Image Access Logs	Images that pass QA are forwarded to secure & backed up centralized PACS
Remote Connection (2-factor authentication)	QIPCM Virtual Desktop Infrastructure (VMs)
Remote Contouring	Installation of desired software onto user VMs (QIPCM-developed contouring workflow)
Personalized Dosimetry, Report Generation and Publishing	Installation of desired software onto user VMs (QIPCM-developed dosimetry plug-in)

Referencing QIPCM in Your Publications

For publications resulting from our services, please acknowledge QIPCM in the Acknowledgements section of your manuscript.

Acknowledgements are an important reflection of our contributions to your published work, and help strengthen our applications for grant funding. We appreciate your acknowledgements!

In general, it is sufficient to reference qipcm.com and/or QIPCM for tracking and reporting purposes. It is not required that Individual team members be named unless they have made a direct scientific contribution to your work that warrants authorship or specific acknowledgement.
To support accurate tracking of core facility usage in publications, please include the following Research Resource Identifier (RRID)*:

– QIPCM – RRID: SCR_027527

* A Research Resource Identifier (RRID) is a unique citation code that enables transparent reporting and recognition of core facilities in published research.

Use Case:

Lu-DOTATATE Treatment in Patients with 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors (ClinicalTrials.gov Identifier: NCT02743741)

Referencing QIPCM in Your Publications

Lu-DOTATATE Treatment in Patients with 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
(ClinicalTrials.gov Identifier: NCT02743741)